scholarly journals A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias

2017 ◽  
Author(s):  
Pamela L. Lutsey ◽  
Lin Y. Chen ◽  
Anne Eaton ◽  
Melanie Jaeb ◽  
Kyle D. Rudser ◽  
...  
Keyword(s):  
Placebo Group ◽  
Pilot Study ◽  
Randomized Trial ◽  
Magnesium Concentration ◽  
Magnesium Supplementation ◽  
Supplement Group ◽  
Gastrointestinal Problems ◽  
Magnesium Supplement ◽  
Oral Magnesium

AbstractBackgroundMagnesium is believed to have a physiologic role in cardiac contractility, and evidence from epidemiologic and clinical studies has suggested that low serum concentrations of magnesium may be associated with increased risk of atrial fibrillation (AF).ObjectiveAs part of the planning effort for a large randomized trial to prevent AF with magnesium supplementation, we conducted a 12-week pilot study to assess adherence to oral magnesium supplementation and matching placebo, estimate the effect on circulating magnesium concentrations, and evaluate the feasibility of using an ambulatory monitoring device (ZioPatch) for assessing premature atrial contractions (PACs), a predictor of AF.DesignDouble-blind randomized pilot clinical trial comparing supplementation with 400 mg magnesium oxide daily (versus placebo) over 12 weeks of follow-up. The ZioPatch was applied for 14 days at baseline and the end of follow-up. Adherence to the assigned treatment, and changes in PACs, serum magnesium concentration, glucose and blood pressure were assessed.ResultsA total of 59 participants, 73% women and average age 62 years, were randomized. 98% of participants completed follow-up. Those assigned to the magnesium supplement took 75% of tablets as compared to 83% for those in the placebo group. Change in magnesium concentrations was significantly greater for those given magnesium supplement compared to placebo (0.07; 95% confidence interval (CI): 0.03, 0.12 mEq/L; p = 0.002). ZioPatch was worn for an average of 13.0 of the requested 14 days at baseline; at the end of follow-up, the average number of days of monitoring was 13.0 days for the magnesium supplement group and 12.7 days for the placebo group. For log PAC burden (episodes per hour), the average change from baseline was −0.05 (95% CI: −0.31, 0.20) for those randomized to magnesium supplement and 0.04 (95% CI: −0.24, 0.31) for those randomized to placebo (p=0.79 for difference). Gastrointestinal problems were reported by 50% of participants in the magnesium supplement group and 7% in the placebo group. Only one person in the magnesium supplement group and none in the placebo group experienced adverse events which led to treatment discontinuation.ConclusionsIn this pilot randomized clinic trial, although gastrointestinal side effects to the magnesium supplement were common, adherence, measured by pill counts, was very good and, as a consequence, magnesium concentrations were greater for those randomly assigned to the magnesium supplement compared to placebo. Participant acceptance of the planned monitoring with ZioPatch was also very good. While the difference in the change in PACs was not significant, this pilot study was small, short-term, and did not include participants at high risk of AF. Thus, we could not reliably evaluate the effect of magnesium supplementation on PACs.Clinicaltrials.gov registrationNCT02837328

No positive effect of oral magnesium supplementation in the decreases of inflammation in subjects with prediabetes: A pilot study

2012 ◽  
Vol 25 (3) ◽  
pp. 140-146 ◽  
Author(s):  
Luis E. Simental-Mendía ◽  
Martha Rodríguez-Morán ◽  
Miguel A. Reyes-Romero ◽  
Fernando Guerrero-Romero
Keyword(s):  
Pilot Study ◽  
Magnesium Supplementation ◽  
Positive Effect ◽  
Oral Magnesium

scholarly journals A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias

Nutrients ◽  
2018 ◽  
Vol 10 (7) ◽  
pp. 884 ◽  
Author(s):  
Pamela Lutsey ◽  
Lin Chen ◽  
Anne Eaton ◽  
Melanie Jaeb ◽  
Kyle Rudser ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Supraventricular Arrhythmias ◽  
Magnesium Supplementation ◽  
Oral Magnesium

scholarly journals Clinical trial on the effects of oral magnesium supplementation in stable-phase COPD patients

2021 ◽  
Author(s):  
Bruno Micael Zanforlini ◽  
Chiara Ceolin ◽  
Caterina Trevisan ◽  
Agnese Alessi ◽  
Daniele Michele Seccia ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Placebo Group ◽  
Lung Function ◽  
Physical Performance ◽  
The Other ◽  
Stable Phase ◽  
Magnesium Supplementation ◽  
Copd Patients ◽  
Oral Magnesium

Abstract Background and aims COPD is a common chronic condition in older age that impacts on daily activities and quality of life. Previous studies suggest that magnesium deficit in COPD patients affects bronco-obstruction, inflammation, and physical performance. We investigated whether oral magnesium supplementation in stable-phase COPD patients improves lung function, physical performance, and quality of life. Methods We conducted a double-blind randomized-controlled clinical study with 49 participants divided into two groups: one given 300 mg/day of magnesium citrate (n = 25) and the other one sachet/day of a placebo (n = 24). The following parameters were assessed at baseline and after 3 and 6 months: lung function (spirometry), physical performance (handgrip strength, lower limb strength, six-minute walk test), inflammation (e.g., C-reactive protein, CRP), disease-related symptoms, and quality of life (St George’s Respiratory Questionnaire, EuroQoL-5D, the Modified British Medical Research Council Questionnaire). Results Linear mixed models revealed significantly lower CRP values in the intervention group than in the placebo group at the 6 month follow-up (β = − 3.2, 95% CI − 6.0, − 0.4, p = 0.03). Moreover, the maximum work for flexion tended to increase in both groups between the 3 and the 6 month assessments, especially in the placebo group. No significant differences within and between groups over the study period were observed for the other parameters tested. Conclusions Although the established minimum sample size was not reached, our results suggests that oral magnesium supplementation may have a potential anti-inflammatory role. On the other hand, it does not seem to substantially influence lung function, physical performance, and quality of life in COPD patients. Trial registration The study is registered in clinicaltrial.gov (Trial Registration: NCT02680769, 13 June 2016, retrospectively registered).

Oral Magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial

2004 ◽  
Vol 30 (3) ◽  
pp. 253-258 ◽  
Author(s):  
F Guerrero-Romero ◽  
HE Tamez-Perez ◽  
G González-González ◽  
AM Salinas-Martínez ◽  
J Montes-Villarreal ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Insulin Sensitivity ◽  
Randomized Trial ◽  
Magnesium Supplementation ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Oral Magnesium

Hypomagnesemia due to two novel TRPM6 mutations

2015 ◽  
Vol 28 (11-12) ◽  
Author(s):  
Michelle Coulter ◽  
Caroline Colvin ◽  
Bruce Korf ◽  
Ludwine Messiaen ◽  
Benjamin Tuanama ◽  
...  
Keyword(s):  
Clinical Presentation ◽  
Seizure Activity ◽  
Neonatal Period ◽  
Serum Magnesium ◽  
Magnesium Concentration ◽  
Magnesium Supplementation ◽  
Generalized Seizures ◽  
Neonatal Hypoparathyroidism ◽  
Hispanic Male ◽  
Oral Magnesium

AbstractAlthough most hypocalcemia with hypomagenesemia in the neonatal period is due to transient neonatal hypoparathyroidism, magnesium channel defects should also be considered.We report a case of persistent hypomagnesemia in an 8-day-old Hispanic male who presented with generalized seizures. He was initially found to have hypomagnesemia, hypocalcemia, hyperphosphatemia and normal parathyroid hormone. Serum calcium normalized with administration of calcitriol and calcium carbonate. Serum magnesium improved with oral magnesium sulfate. However, 1 week after magnesium was discontinued, serum magnesium declined to 0.5 mg/dL. Magnesium supplementation was immediately restarted, and periodic seizure activity resolved after serum magnesium concentration was maintained above 0.9 mg/dL. The child was eventually weaned off oral calcium and calcitriol with persistent normocalemia. However, supraphysiologic oral magnesium doses were necessary to prevent seizures and maintain serum magnesium at the low limit of normal.As his clinical presentation suggested primary renal magnesium wastage,Two novel

scholarly journals Effect of Memantine on Prolonging Safe Driving in Early AD: a Pilot Study

2021 ◽  
Vol 24 (4) ◽  
pp. 292-296
Author(s):  
Peter J. Holland ◽  
Ruth M. Tappen ◽  
David O. Newman ◽  
Katherine C. Freeman-Costin ◽  
Lori J. Fisher
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Pilot Study ◽  
Randomized Trial ◽  
Driving Ability ◽  
Double Blind ◽  
Screening Criteria ◽  
Safe Driving ◽  
Potential Effectiveness ◽  
Test Outcomes

 Background  To determine the feasibility of conducting an RCT on the potential effectiveness of memantine hydrochloride in prolonging safe driving in mild AD.  Methods  A placebo-controlled, double blind randomized trial was conducted. Forty-three individuals ≥60 with mild AD met screening criteria and were randomized. Driving ability was measured by a standardized on-road driving test. Outcomes were driving capacity at 6 and 12 months and completion of the 12-month intervention.  Results  Of 43 participants randomized, 59% of the memantine group and 52% of the placebo group completed the on-road test at 12 months (p = .66). All 13 memantine group participants maintained their driving status at 12 months, whereas only 8 of the 11 placebo group participants did (p = .040, OR = 4.45).  Conclusions  Results provide the framework for designing a rigorous multisite clinical trial of memantine effect on maintaining driving capacity in mild AD. 

A Pilot Study of Mobile Telephone Message Interventions with Suicide Attempters in China

Crisis ◽  
2010 ◽  
Vol 31 (2) ◽  
pp. 109-112 ◽  
Author(s):  
Hui Chen ◽  
Brian L. Mishara ◽  
Xiao Xian Liu
Keyword(s):  
Pilot Study ◽  
Effective Means ◽  
Text Message ◽  
Text Messages ◽  
Mobile Telephone ◽  
Future Research ◽  
Quick Method ◽  
Suicide Attempters ◽  
To Receive

Background: In China, where follow-up with hospitalized attempters is generally lacking, there is a great need for inexpensive and effective means of maintaining contact and decreasing recidivism. Aims: Our objective was to test whether mobile telephone message contacts after discharge would be feasible and acceptable to suicide attempters in China. Methods: Fifteen participants were recruited from suicide attempters seen in the Emergency Department in Wuhan, China, to participate in a pilot study to receive mobile telephone messages after discharge. All participants have access to a mobile telephone, and there is no charge for the user to receive text messages. Results: Most participants (12) considered the text message contacts an acceptable and useful form of help and would like to continue to receive them for a longer period of time. Conclusions: This suggests that, as a low-cost and quick method of intervention in areas where more intensive follow-up is not practical or available, telephone messages contacts are accessible, feasible, and acceptable to suicide attempters. We hope that this will inspire future research on regular and long-term message interventions to prevent recidivism in suicide attempters.

Sign in / Sign up

Export Citation Format

Share Document